TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,469,316 | +83.3% | 178,749 | +71.9% | 0.00% | – |
| Q1 2024 | $801,686 | -10.3% | 103,980 | +4.6% | 0.00% | – |
| Q4 2023 | $893,831 | +0.6% | 99,425 | 0.0% | 0.00% | – |
| Q3 2023 | $888,860 | -55.4% | 99,425 | +12.3% | 0.00% | -100.0% |
| Q2 2023 | $1,991,378 | 0.0% | 88,545 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,991,378 | +48.9% | 88,545 | +39.3% | 0.00% | 0.0% |
| Q4 2022 | $1,337,045 | -99.9% | 63,578 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $1,538,177,000 | -4.1% | 62,426 | -5.7% | 0.00% | 0.0% |
| Q2 2022 | $1,603,177,000 | -7.4% | 66,165 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $1,731,255,000 | -11.7% | 67,181 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $1,961,355,000 | +56.2% | 63,188 | +22.0% | 0.00% | 0.0% |
| Q3 2021 | $1,255,543,000 | +60.7% | 51,775 | -3.3% | 0.00% | – |
| Q2 2021 | $781,353,000 | -36.6% | 53,554 | +8.4% | 0.00% | -100.0% |
| Q1 2021 | $1,233,143,000 | +17.0% | 49,385 | +27.7% | 0.00% | – |
| Q4 2020 | $1,054,359,000 | – | 38,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |